Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth

Molecular Cancer Therapeutics

Volumn 9, Issue 2, 2010, Pages 429-437

  Cook, Mackenzie R ^a   Pinchot, Scott N ^a   Jaskula Sztul, Renata ^a   Luo, Jie ^a   Kunnimalaiyaan, Muthusamy ^a   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; LEFLUNOMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAF PROTEIN; SEROTONIN; TERIFLUNOMIDE; TRANSCRIPTION FACTOR MASH1; ANTINEOPLASTIC AGENT; CROTONIC ACID DERIVATIVE; ISOXAZOLE DERIVATIVE; TOLUIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL CARCINOID; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SURVIVAL; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOGRANIN A; CROTONATES; ENZYME ACTIVATION; GASTROINTESTINAL NEOPLASMS; HUMANS; ISOXAZOLES; MICE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-RAF; SEROTONIN; TOLUIDINES;

EID: 76649101419     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0718     Document Type: Article

References (44)

1. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. Int MS J 2008;15:62-8.
2. Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 2004;26:447-59.
3. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
4. Baumann P, Mandl-Weber S, Volkl A, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009;8:366-75.
5. Mall JW, Myers JA, Xu X, Saclarides TJ, Philipp AW, Pollmann C. Leflunomide reduces the angiogenesis score and tumor growth of subcutaneously implanted colon carcinoma cells in the mouse model. Chirurg 2002;73:716-20.
6. Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. The immunomodulatory drug leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 2008;22:635-8.
7. Xu X, Williams JW, Gong H, Finnegan A, Chong AS. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 1996;52:527-34.
8. Xu X, Shen J, Mall JW, et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol 1999;58:1405-13.
9. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J Immunol 1999;162:2095-102.
10. Davis Z, Moertel C, McIlrath D. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973;137:637-44.
11. Janson E, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-90.
12. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12 Suppl 2:S69-72.
13. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Chen H. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 2003;134:866-71; discussion 71-3.
14. Jiang S, Kameya T, Asamura H, et al. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol 2004; 17:222-9.
15. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist 2008;13:1255-69.
16. Chen H, Hardacre J, Uzar A, Cameron J, Choti M. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187:88-92; discussion-3.
17. Lal A, Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol 2006;18:9-15.
18. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59.
19. Sippel RS, Chen H. Carcinoid tumors. Surg Oncol Clin N Am 2006; 15:463-78.
20. Van Gompel JJ, Sippel RS, Warner TF, Chen H. Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg 2004;28: 387-92.
21. Chen H, Kunnimalaiyaan M, Van Gompel JJ. Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid 2005;15:511-21.
22. Kunnimalaiyaan M, Chen H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 2006;17:139-42.
23. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Lagerholm S, Chen H. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G245-54.
24. Vaccaro A, Chen H, Kunnimalaiyaan M. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs 2006;17:849-53.
25. Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 2005;4:910-7.
26. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90.
27. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007;12:942-51.
28. Stark G, Taylor W. Control of the G2/M transition. Mol Biotechnol 2006;32:227-48.
29. Tyagi A, Singh R, Agarwal C, Chan D, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002;8:3512-9.
30. Emery P. Leflunomide: a new DMARD for rheumatoid arthritis. Hosp Med 2000;61:344-7.
31. Chen H, Biel MA, Borges MW, et al. Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions. Cell Growth Differ 1997;8:677-86.
32. Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001;13:55-8.
33. Sriuranpong V, Borges MW,Ravi RK, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001;61:3200-5.
34. Chen H, Carson-Walter EB, Baylin SB, Nelkin BD, Ball DW. Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1. Surgery 1996;120:168-72; discussion 73.
35. Chambard J, Lefloch R, Pouysségur J, Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta 2007;1773: 1299-310.
36. Nam H, Kim S, Lee M, et al. The ERK-RSK1 activation by growth factors at G2 phase delays cell cycle progression and reduces mitotic aberrations. Cell Signal 2008;20:1349-58.
37. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. J Surg Res 2010. In press.
38. Kunnimalaiyaan M, Ndiaye M, Chen H. Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery 2007;142:959-64.
39. Kunnimalaiyaan M, Ndiaye M, Chen H. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 2006;140:1009-15.
40. Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 2001;81:527-42.
41. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
42. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406.
43. Pinchot SN, Adler JT, Luo Y, et al. Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg 2009;197:313-9.
44. Chong AS, Huang W, Liu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999;68:100-9.